Francine Foss, MD

Francine Foss, MD, and Matthew Lunning, DO, FACP, discuss other key data from ASH 2025 and ongoing research to watch in peripheral T-cell lymphoma.

Francine Foss, MD, and Matthew Lunning, DO, FACP, discuss findings for duvelisib plus chidamide and CHOP in newly diagnosed angioimmunoblastic T-cell lymphoma.

Francine Foss, MD, and Matthew Lunning, DO, FACP, look ahead to the phase 3 TERZO trial of duvelisib in nodal TFH peripheral T-cell lymphoma.

Francine Foss, MD, and Matthew Lunning, DO, FACP, highlight key findings from the PRIMO trial evaluating duvelisib in relapsed/refractory peripheral T-cell lymphoma.

Francine Foss, MD, and Matthew Lunning, DO, FACP, discuss varying treatment approaches for peripheral T-cell lymphoma in newly diagnosed vs relapsed disease.

Francine Foss, MD, and Matthew Lunning, DO, FACP, detail current treatment approaches for peripheral T-cell lymphoma.

Francine Foss, MD, discusses the FDA approval of denileukin diftitox for the treatment of patients with CTCL.

Dr Foss discusses the significance of the FDA approval of denileukin diftitox for patients with relapsed/refractory CTCL.

Francine Foss, MD, discusses pursing new therapeutic options for the treatment of patients with T-cell non-Hodgkin lymphoma.

Francine Foss, MD, discusses the challenges faced in cutaneous T-cell lymphoma.